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Abstract 39 
We assessed Plasmodium falciparum drug resistance markers in parasites collected in 2012, 40 
2013, and 2015 at 3 sites in Uganda. The prevalence and frequency of parasites with mutations 41 
in putative transporters previously associated with resistance to aminoquinolines, but increased 42 
sensitivity to lumefantrine (pfcrt 76T; pfmdr1 86Y and 1246Y), decreased markedly at all sites. 43 
Antifolate resistance mutations were common, with apparent emergence of mutations (pfdhfr 44 
164L; pfdhps 581G) associated with high level resistance. K13 mutations linked to artemisinin 45 
resistance were uncommon and did not increase over time. Changing malaria treatment 46 
practices have been accompanied by profound changes in markers of resistance. 47 
 48 
 49 
 Drug resistance challenges the treatment and control of malaria. In Africa, use of 50 
artemisinin-based combination therapies (ACTs) has become standard to treat uncomplicated 51 
malaria, accompanied by changes in the selective pressure for resistance. In Uganda, the first 52 
line regimen to treat uncomplicated malaria changed from chloroquine to chloroquine + 53 
sulfadoxine/pyrimethamine in 2000 and artemether-lumefantrine (AL) in 2004, although 54 
implementation was slow. Elsewhere in Africa, artesunate-amodiaquine (AS/AQ) is first line to 55 
treat malaria in many countries and dihydroartemisinin-piperaquine (DHA/PQ) is under study for 56 
chemoprevention. SP remains the standard-of-care to prevent malaria in pregnant women.  57 
 Our understanding of antimalarial drug resistance is incomplete, but some Plasmodium 58 
falciparum genetic polymorphisms are clearly important. The 76T mutation in the putative 59 
transporter PfCRT is linked to decreased sensitivity to the aminoquinolines chloroquine and 60 
amodiaquine, and pfcrt mutations are selected in new infections that occur soon after treatment 61 
with aminoquinolines [1, 2]. Mutations in pfmdr1, which encodes another putative transporter, 62 
the p-glycoprotein homologue, are also associated with altered drug sensitivity. In Africa, the 63 
pfmdr1 86Y and 1246Y mutations are common, associated with decreased sensitivity to 64 
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aminoquinolines, and selected by prior treatment with AS/AQ and DHA/PQ [1, 3]. Interestingly, 65 
wild type sequences at these same alleles are associated with decreased sensitivity to 66 
lumefantrine and selected by recent treatment with AL, demonstrating opposite effects of the 67 
same polymorphisms on sensitivity to different drugs [1, 2].   68 
 Resistance to SP is well characterized, with 5 mutations in dihydrofolate reductase (51I, 69 
59R, and 108N) and dihydropteroate synthetase (437G and 540E) now common in much of 70 
Africa and associated with an intermediate level of resistance [4]. Additional mutations, notably 71 
pfdhfr 164L and pfdhps 581G, lead to high level resistance. These mutations have been rare in 72 
African surveys, but recent studies have suggested emergence in some areas [5, 6].  73 
 Changing malaria treatment practices may lead to changes in drug sensitivity. In Malawi, 74 
the replacement of chloroquine with SP was followed by widespread pfcrt wild type parasites 75 
and excellent clinical efficacy of chloroquine [7]. In Uganda, increased prevalence of wild type 76 
pfcrt K76 and pfmdr1 N86 and D1246 sequences was seen in Tororo from 2003-12 [2, 8], 77 
although analyses were complicated by numerous mixed genotypes. In ex vivo studies, 78 
increasing sensitivity to chloroquine and decreasing sensitivity to lumefantrine were 79 
documented [2]. Consistent with these changes, and in contrast to older studies that showed 80 
superiority of AL, in a recent 3-site trial, treatment with AS/AQ was followed by decreased 81 
recurrent malaria compared to AL [9]. Thus, parasites in Uganda are changing, and these 82 
changes appear to have clinical consequences. However, improved measures of parasite 83 
trends will be helpful, in particular utilizing randomly collected samples rather than those 84 
available from drug efficacy trials, and including analyses of frequency, which circumvent the 85 
complexities of polyclonal infections. We now report the prevalence and frequency of key 86 
polymorphisms utilizing samples collected by probability sampling. 87 
 88 
 89 
 90 
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METHODS 91 
Cross-sectional surveys and sample collection. Cross-sectional surveys were conducted in 92 
200 randomly selected households each at 3 sites in 2012, 2013, and 2015 as previously 93 
described [10]. Samples were collected during the same period for each year of the study, 94 
January-February in Nagongera, Tororo District, in eastern Uganda near Kenya; March-April in 95 
Walukuba, Jinja District, in south-central Uganda on Lake Victoria; and May-June in Kihihi, 96 
Kanungu District, in southwestern Uganda. The sites varied greatly in malaria transmission 97 
intensity (annual entomological inoculation rates 3.8, 26.6, and 125.0 infectious bites per person 98 
year for Walukuba, Kihihi, and Nagongera, respectively). Households were randomly selected 99 
as described, and finger prick blood samples collected on filter paper from all children under 15 100 
years of age and 1 randomly selected adult from each of 5 age categories; samples were 101 
collected regardless of whether symptoms were present [10]. 102 
 103 
Assessment of P. falciparum polymorphisms. Parasite DNA was extracted from dried blood 104 
spots from samples positive by microscopy, and sequences of alleles of interest in pfcrt, pfmdr1, 105 
pfdhfr, and pfdhps were determined using a ligase detection reaction-fluorescent microsphere 106 
assay, as previously described [11], with minor modifications, including nested PCR 107 
amplifications of templates, as described [12]. The K13 gene propeller domain was amplified 108 
and sequenced as previously described [13].  109 
 110 
Frequency and linkage analyses. Parasite population frequencies were estimated using all 111 
1466 samples and a previously described model that accounts for mixed infections [14]. Linkage 112 
disequilibrium was estimated for all samples, but results from alleles with mixed or missing 113 
genotyping outcomes were omitted from the analysis (see supplementary file for details). 114 
 115 
 116 
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RESULTS 117 
Prevalence of resistance-mediating polymorphisms in putative transporters. A total of 118 
1486 microscopy-positive samples were collected and analyzed. Sequences at all alleles of 119 
interest were classified as wild type (identical in sequence to the reference 3D7 strain), mutant, 120 
or mixed for the 1466 samples that yielded data for at least one polymorphism. Considering the 121 
key transporter polymorphisms pfcrt K76T, pfmdr1 N86Y, and pfmdr1 D1246Y, the prevalence 122 
of parasites with mutant sequences decreased steadily from 2012 to 2015 (Figure 1A). Results 123 
were similar at the 3 sites. For another polymorphic allele, pfmdr1 Y184F, the prevalence of 124 
parasites with mutant alleles increased in Jinja, but was stable at other sites. The pfmdr1 1034C 125 
and 1042D mutations, generally seen only outside Africa, were identified rarely. 126 
 127 
Prevalence of resistance-mediating polymorphisms in folate pathway enzymes. The 128 
prevalence of parasites with 5 mutations (pfdhfr 51I, 59R, 108N; pfdhps 437G, 540E) that were 129 
common in prior surveys remained high (Figure 1A). In addition, 2 mutations that have 130 
previously been rare in most surveys from Africa were seen, with pfdhfr 164L in Kanungu, and 131 
pfdhps 581G at all 3 sites in in 2015.  132 
 133 
Frequency of resistance-mediating polymorphisms and haplotype analysis. Prevalence 134 
data did not take into account multiplicity of infection (MOI) and were complicated by many 135 
samples containing both wild type and mutant sequences. Therefore, we used a statistical 136 
model to estimate parasite population frequencies for the studied polymorphisms. Frequency 137 
results were broadly similar to those based on prevalence; point estimates for the mutant 138 
transporter alleles pfcrt 76T, pfmdr1 86Y, and pfmdr1 1246Y decreased markedly from 2012 to 139 
2015 at all 3 sites (Figure 1B). Estimates of linkage disequilibrium suggested linkage between 140 
pfmdr1 86, 184, and 1246, and pfcrt 76; between pfmdr1 1246 and pfcrt 76; and between 141 
pfdhps 437 and 540 (Figure 2). Considering haplotypes, Y184F did not appear to impact trends, 142 
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with increases in both NYD and NFD haplotypes over time (Supplemental Figure 1); there was a 143 
marked increase in frequency of the pfmdr1 N86/D1246 haplotype, suggesting that parasites 144 
with both wild type alleles have a selective advantage (Supplemental Figure 2); and the wild 145 
type pfmdr1 N86/D1246 haplotype was associated with both pfcrt K76T alleles, while K76 was 146 
associated only with N86/D1246 (Supplemental Figure 3).  147 
 148 
Prevalence of K13 polymorphisms. We randomly selected 20 samples from each site and 149 
year for analysis. Of the 153 sequences obtained, 4 samples had non-synonymous 150 
polymorphisms, with a total of 5 mutations, each identified once (V555A from Kihihi in 2012; 151 
M472V from Nagongera in 2013; A569S from Nagongera in 2015; K563E and A578S in a single 152 
sample from Walukuba in 2013). K13 mutations were seen in samples from all 3 sites and all 3 153 
years of study. Mutations at 4 of the loci were reported previously in Africa, from Niger (M472I), 154 
Rwanda (V555A), Kenya and Cameroon (A569S), and 7 different countries, including Uganda 155 
(A578S), but to our knowledge K563E has not been reported (http://www.wwarn.org/molecular-156 
surveyor-k13).  157 
 158 
DISCUSSION 159 
We surveyed the prevalence and calculated the frequency of key drug resistance 160 
polymorphisms in P. falciparum isolates collected at 3 sites in Uganda from 2012 to 2015. This 161 
study improved on prior evaluations by studying randomly collected isolates, rather than those 162 
collected in the context of a clinical trial, and by evaluating the frequency of polymorphisms, 163 
circumventing confounding by varied MOI and prevalence of mixed infections at different sites. 164 
We identified important changes over time. Notably, with increasing use of AL to treat malaria, 165 
the prevalence and frequency of mutant sequences at 3 key pfcrt and pfmdr1 alleles decreased, 166 
consistent with decreasing sensitivity to lumefantrine, but increasing sensitivity to 167 
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aminoquinolines. In addition, mutations in pfdhfr and pfdhps that mediate high level antifolate 168 
resistance appear to be emerging. 169 
Changes in the prevalence of parasites with drug resistance polymorphisms were not 170 
unexpected. In Malawi, discontinuation of chloroquine as the first-line antimalarial was 171 
accompanied by loss of the pfcrt 76T mutation and regaining of chloroquine antimalarial efficacy 172 
[7]. Multiple studies showed selection for mutant genotypes by amodiaquine-containing 173 
regimens and for wild type genotypes by AL [1]. In Uganda, wild type sequences at 3 key 174 
transporter alleles are increasingly common. Most parasites studied in Tororo were mutant at 175 
these 3 alleles through about 2010 [8], but wild type sequences have been increasingly 176 
prevalent since that time. The rate of change toward wild type transporter sequences was 177 
greater in a cohort treated with AL for every episode of malaria, compared to a cohort treated 178 
with DHA/PQ, documenting the contribution of selective pressure from AL to this process [12].  179 
Mutations in pfdhfr and pfdhps have been common in Uganda for at least a decade. Use 180 
of SP to treat malaria, WHO-recommended SP for intermittent preventive therapy in pregnant 181 
women, antifolates to treat bacterial infections, and trimethoprim-sulfamethoxazole in HIV-182 
infected individuals likely all offer continued selective pressure for antifolate resistance. It was 183 
thus of interest to see if additional mutations that have been seen primarily outside Africa [4] are 184 
emerging in Uganda. The pfdhfr 164L mutation was identified in an earlier survey in 185 
southwestern Uganda [5], and it was present in Kanungu, also in southwestern Uganda, over 186 
the course of our study. The pfdhps 581G mutation, which has been noted in Tanzania [6], was 187 
detected at all 3 study sites. These additional mutations will probably render SP useless for the 188 
treatment or control of malaria. Consideration of other regimens for the prevention of malaria, 189 
notably DHA/PQ, which recently showed outstanding efficacy in children and pregnant women 190 
[3, 15], is an urgent priority. 191 
Frequency analyses clarified results by accounting for MOI and mixed infections, and 192 
were consistent with prevalence results. Linkage analyses demonstrated linkage between the 193 
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transporter polymorphisms pfmdr1 86, 184, 1246, and pfcrt 76. Haplotype analyses 194 
demonstrated an apparent selective advantage of parasites with the wild type alleles pfmdr1 195 
N86 and D1246, and that wild type pfcrt K76 was present almost exclusively with a background 196 
of pfmdr1 N86/D1246. As pfcrt 76T is the main mediator of resistance to chloroquine, but 197 
decreased sensitivity to lumefantrine is linked to all 3 of these polymorphisms [1, 2], it seems 198 
likely that the evolution of transporter polymorphisms has been driven both by decreasing use of 199 
chloroquine and increasing use of AL over time.   200 
Resistance to artemisinins, mediated principally by mutations in K13, is of great concern, 201 
but resistance does not appear to have yet spread to Africa. We identified a handful of K13 202 
propeller domain mutations, but no evidence of geographic differences in prevalence or 203 
changes over time. K13 polymorphisms may be under selection from ACT use in Uganda, but 204 
they do not yet appear to be mediating artemisinin resistance. 205 
Our study had some limitations. First, we studied only 3 sites over 4 years; important 206 
additional trends may be underway, but not evident over this short interval. Second, sample 207 
sizes were fairly small, especially for Jinja, where decreasing prevalence limited available 208 
samples over time. Third, we considered only a small number of well characterized resistance-209 
mediating polymorphisms. Consideration of full sequences of genes of interest or of whole 210 
genomes might identify additional important trends in the evolution of drug resistance. 211 
In summary, surveillance for P. falciparum drug resistance markers in Uganda has 212 
demonstrated marked changes in recent years, with a return to wild type transporter sequences 213 
that likely mediate decreased sensitivity to AL, the national regimen to treat malaria, emergence 214 
of mutations that mediate high level antifolate resistance, but no convincing evidence of 215 
artemisinin resistance. Continued surveillance for mediators of antimalarial drug resistance is 216 
warranted. Furthermore, as selective pressures of AS/AQ and DHA/PQ differ from those of AL 217 
[1-3, 9, 12], we suggest consideration of rotating treatment regimens to delay emergence of 218 
resistance. 219 
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Figure 1. 
 
 
 
 
Figure 1. A. Prevalence of wild type, mixed, or mutant sequences at alleles of interest at 
the indicated sites and years. The numbers under the dates represent the number of samples 
generating results. Asterisks represent p-values based on comparisons with pure wild type 
infections  for pfmdr1 and pfcrt and pure mutant infections for pfdhfr and pfdhps using the 
Fisher’s exact test (***<0.001, **<0.01,* <0.05). B. Frequency of mutant sequences. Error 
bars represent 95% credible intervals.  
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Figure 2. 
 
 
Figure 2. Plot of linkage disequilibrium for pairwise comparisons of all studied pfcrt, 
pfmdr1, pfdhfr, and pfdhps polymorphisms. Linkage disequilibrium, r2, captures the non-
random association of alleles within one gene or in different genes, with values ranging from 0 
(no correlation) to 1 (perfect correlation). Colors indicate r2 values (see supplementary file for 
details), calculable for polymorphic markers only; white denotes non-polymorphic markers. P-
values of statistically significant r2 values are shown. These were calculated using Fisher’s exact 
test, with a Bonferroni correction for 45 tests over 10 polymorphic markers, placing significance 
at 0.001.   
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Supplement to Tumwebaze, et al.: Changing antimalarial drug resistance patterns 
identified by surveillance at three sites in Uganda 
 
SUPPLEMENTAL METHODS 
Frequency analyses 
Frequencies were estimated using a previously published model [1] applied to data from 
different sites and years separately. We used a Dirichlet prior with concentration parameter 
equal to 0.1 over frequencies and a truncated geometric prior over each multiplicity of infection 
(MOI), 𝜌(𝑀𝑂𝐼) =  
𝜆 (1−𝜆)𝑀𝑂𝐼
∑ 𝜆 (1−𝜆)𝑀𝑂𝐼
𝑀𝑂𝐼𝑚𝑎𝑥
𝑀𝑂𝐼=𝑀𝑂𝐼𝑚𝑖𝑛
, where 𝑀𝑂𝐼𝑚𝑖𝑛 = 1, or 2 if the sample was discernibly 
multiclonal, 𝑀𝑂𝐼𝑚𝑎𝑥 = 20, and 𝜆 was based on experimentally derived MOI estimates by 
genotyping the msp2 locus via nested PCR and capillary electrophoresis [2]. To account for 
ambiguity in MOI estimates greater than or equal to 5, the frequency results were generated by 
combining a posteriori samples from two separate runs of the model, one with 𝜆 equal to the 
reciprocal of the sample mean MOI per site and year, and one with 𝜆 equal to the reciprocal of 
the mean MOI over samples with MOI less than or equal to 5 per site and year.  
 
Linkage analyses 
Linkage disequilibrium, r2 [3], was estimated for all studied pfcrt, pfmdr1, pfdhfr, and pfdhps 
polymorphisms, using data from all 1466 samples yielding results, but discarding counts with 
one or more mixed or missing genotyping outcomes from within-calculation quotients. P-values 
were calculated using Fisher’s exact test. For 45 tests over 10 polymorphic markers, a 
Bonferroni correction on uncorrected significance at 0.05 placed significance at 0.001. 
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Supplemental Table 1. Prevalence of wild type, mixed, or mutant sequences at 272 
transporter alleles of interest at the indicated sites and years. N = number of samples. 273 
 274 
Locus Site Year N Wild type Mixed Mutant 
Pfmdr1 N86Y Jinja 2012 61 11 (18.0%) 27 (44.3%) 23 (37.7%) 
Jinja 2013 45 30 (66.7%) 13 (28.9%) 2 (4.4%) 
Jinja 2015 36 31 (86.1%) 5 (13.9%) 0 
Kanungu 2012 77 15 (19.5%) 34 (44.2%) 28 (36.4%) 
Kanungu 2013 60 36 (60.0%) 16 (26.7%) 8 (13.3%) 
Kanungu 2015 114 105 (92.1%) 7 (6.1%) 2 (1.8%) 
Tororo 2012 317 128 (40.4%) 163 (51.4%) 26 (8.2%) 
Tororo 2013 363 170 (46.8%) 151 (41.6%) 42 (11.6%) 
Tororo 2015 282 229 (81.2%) 51 (18.1%) 2 (0.7%) 
Pfmdr1 Y184F Jinja 2012 64 34 (53.1%) 21 (32.8%) 9 (14.1%) 
Jinja 2013 47 18 (38.3%) 23 (48.9%) 6 (12.8%) 
Jinja 2015 32 9 (28.1%) 14 (43.8%) 9 (28.1%) 
Kanungu 2012 80 37 (46.3%) 27 (33.8%) 16 (20.0%) 
Kanungu 2013 59 27 (45.8%) 22 (37.3%) 10 (17.0%) 
Kanungu 2015 109 40 (36.7%) 40 (36.7%) 29 (26.6%) 
Tororo 2012 316 99 (31.3%) 147 (46.5%) 70 (22.2%) 
Tororo 2013 361 184 (51.0%) 124 (34.4%) 53 (14.7%) 
Tororo 2015 274 88 (32.1%) 112 (40.9%) 74 (27.0%) 
Pfmdr1 S1034C Jinja 2012 72 72 (100%) 0  0 
Jinja 2013 47 47 (100%) 0 0 
Jinja 2015 15 15 (100%) 0 0 
Kanungu 2012 81 81 (100%) 0 0 
Kanungu 2013 67 67 (100%) 0 0 
Kanungu 2015 59 59 (100%) 0 0 
Tororo 2012 174 174 (100%) 0 0 
Tororo 2013 374 374 (100%) 0 0 
Tororo 2015 158 158 (100%) 0 0 
 Pfmdr1 N1042D Jinja 2012 72 72 (100%) 0 0 
Jinja 2013 47 46 (97.9%) 1 (2.1%) 0 
Jinja 2015 15 15 (100%) 0 0 
Kanungu 2012 81 81 (100%) 0 0 
Kanungu 2013 55 54 (98.2%) 1 (1.8%) 0 
Kanungu 2015 65 65 (100%) 0 0 
Tororo 2012 167 167 (100%) 0 0 
Tororo 2013 363 361 (99.5%) 2 (0.6%) 0 
Tororo 2015 159 159 (100%) 0 0 
Pfmdr1 D1246Y Jinja 2012 62 24 (38.7%) 24 (38.7%) 14 (22.6%) 
Jinja 2013 45 33 (73.3%) 9 (20.0%) 3 (6.7%) 
Jinja 2015 35 28 (80.0%) 6 (17.1%) 1 (2.9%) 
Kanungu 2012 79 28 (35.4%) 35 (44.3%) 16 (20.3%) 
Kanungu 2013 61 47 (77.1%) 6 (9.8%) 8 (13.1%) 
Kanungu 2015 116 92 (79.3%) 18 (15.5%) 6 (5.2%) 
Tororo 2012 300 149 (49.7%) 107 (35.7%) 44 (14.7%) 
Tororo 2013 362 233 (64.4%) 103 (28.5%) 26 (7.2%) 
Tororo 2015 286 205 (71.7%) 65 (22.7%) 16 (5.6%) 
Pfcrt K76T Jinja 2012 70 3 (4.3%) 0 67 (95.7%) 
Jinja 2013 50 2 (4.0%) 5 (10.0%) 43 (86.0%) 
Jinja 2015 35 5 (14.3%) 6 (17.1%) 24 (68.6%) 
17 
 
Kanungu 2012 86 3 (3.5%) 2 (2.3%) 81 (94.2%) 
Kanungu 2013 66 10 (15.2%) 13 (19.7%) 43 (65.2%) 
Kanungu 2015 117 35 (29.9%) 13 (11.1%) 69 (59.0%) 
Tororo 2012 342 9 (2.6%) 45 (13.2%) 288 (84.2%) 
Tororo 2013 378 39 (10.3%) 51 (13.5%) 288 (76.2%) 
Tororo 2015 285 85 (29.8%) 54 (19.0%) 146 (51.2%) 
 275 
  276 
18 
 
Supplemental Table 2. Prevalence of wild type, mixed, or mutant sequences at antifolate 277 
alleles of interest at the indicated sites and years. N = number of samples. 278 
 279 
Locus Site Year N Wild type Mixed Mutant 
Pfdhfr N51I Jinja 2012 66 0 0 66 (100%) 
Jinja 2013 49 0 0 49 (100%) 
Jinja 2015 35 0 0 35 (100%) 
Kanungu 2012 72 0 0 72 (100%) 
Kanungu 2013 60 1 (1.7%) 4 (6.7%) 55 (91.7%) 
Kanungu 2015 110 0 0 110 (100%) 
Tororo 2012 258 0 0 258 (100%) 
Tororo 2013 198 0 0 198 (100%) 
Tororo 2015 279 0 0 279 (100%) 
Pfdhfr C59R Jinja 2012 66 1 (1.5%) 2 ( 3.0%) 63 (95.5%) 
Jinja 2013 49 1 (2.0%) 6 (12.2%) 42 (85.7%) 
Jinja 2015 35 1 (2.9%) 7 (20.0%) 27 (77.1%) 
Kanungu 2012 74 2 (2.7%) 8 (10.8%) 64 (86.5%) 
Kanungu 2013 60 6 (10.0%) 4 (6.7%) 50 (83.3%) 
Kanungu 2015 118 3 (2.5%) 9 (7.6%) 106 (89.8%) 
Tororo 2012 254 2 (0.8%) 22 (8.7%) 230 (90.6%) 
Tororo 2013 198 3 (1.5%) 19 (9.6%) 176 (88.9%) 
Tororo 2015 293 3 (1.0%) 29 (9.9%) 261 (89.1%) 
Pfdhfr S108T/N Jinja 2012 66 0 0 66 (100%) 
Jinja 2013 49 0 0 49 (100%) 
Jinja 2015 36 0 0 36 (100%) 
Kanungu 2012 72 0 0 72 (100%) 
Kanungu 2013 60 0 0 60 (100%) 
Kanungu 2015 110 0 0 110 (100%) 
Tororo 2012 255 0 0 255 (100%) 
Tororo 2013 198 0 0 198 (100%) 
Tororo 2015 282 0 0 282(100%) 
Pfdhfr I164L Jinja 2012 65 65 (100%) 0 0 
Jinja 2013 46 46 (100%) 0 0 
Jinja 2015 35 35 (100%) 0 0 
Kanungu 2012 69 64 (92.8%) 2 (2.9%) 3 (4.4%) 
Kanungu 2013 55 48 (87.3%) 2 (3.6%) 5 (9.1%) 
Kanungu 2015 115 103 (89.6%) 5 (4.4%) 7 (6.1%) 
Tororo 2012 253 253 (100%) 0 0 
Tororo 2013 196 196 (100%) 0 0 
Tororo 2015 294 294 (100%) 0 0 
Pfdhps A437G Jinja 2012 35 0 0 35 (100%) 
Jinja 2013 41 0 0 41 (100%) 
Jinja 2015 33 0 3 (9.1%) 30 (90.9%) 
Kanungu 2012 56 0 0 56 (100%) 
Kanungu 2013 50 0 0 50 (100%) 
Kanungu 2015 117 7 (6.0%) 6 (5.1%) 104 (88.9%) 
Tororo 2012 263 4 (1.5%) 18 (6.8%) 241 (91.6%) 
Tororo 2013 185 0 2 (1.1%) 183 (98.9%) 
Tororo 2015 268 5 (1.9%) 26 (9.7%) 237 (88.4%) 
Pfdhps K540E Jinja 2012 37 0 0 37 (100%) 
Jinja 2013 44 0 2 (4.6%) 42 (95.5%) 
Jinja 2015 33 0 0 33 (100%) 
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Kanungu 2012 61 1 (1.6%) 0 60 (98.4%) 
Kanungu 2013 51 0 2 (3.9%) 49 ( 96.1%) 
Kanungu 2015 105 4 (3.9%) 3 (2.9%) 98 (93.3%) 
Tororo 2012 265 2 (0.8%) 4 (1.5%) 259 (97.7%) 
Tororo 2013 187 1 (0.5%) 4 (2.1%) 182 (97.3%) 
Tororo 2015 256 7 (2.7%) 9 (3.5%) 240 (93.8%) 
Pfdhps A581G Jinja 2012 46 45 (97.8%) 1 (2.2%) 0 
Jinja 2013 44 43 (97.7%) 1 (2.3%) 0 
Jinja 2015 38 30 (79.0%) 1 (2.6%) 7 (18.4%) 
Kanungu 2012 61 42 (68.9%) 8 (13.1%) 11 (18.0%) 
Kanungu 2013 50 31 (62.0%) 6 (12.0%) 13 (26.0%) 
Kanungu 2015 117 77 (65.8%) 31 (26.5%) 9 (7.7%) 
Tororo 2012 268 254 (94.8%) 13 (4.9%) 1 (0.4%) 
Tororo 2013 188 179 (95.2%) 7 (3.7%) 2 (1.1%) 
Tororo 2015 261 226 (86.6%) 24 (9.2%) 11 ( 4.2%) 
Pfdhps A613S Jinja 2012 31 31 (100%) 0 0 
Jinja 2013 44 44 (100%) 0 0 
Jinja 2015 35 35 (100%) 0 0 
Kanungu 2012 58 58 (100%) 0 0 
Kanungu 2013 45 45 (100%) 0 0 
Kanungu 2015 110 110 (100%) 0 0 
Tororo 2012 260 259 (99.6%) 1 (0.4%) 0 
Tororo 2013 181 181 (100%) 0 0 
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Supplemental Figure 1. Frequency point estimates of pfmdr1 N86Y/Y184F/D1246Y 
haplotypes. Error bars represent 95% credible intervals. 
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Supplemental Figure 2. Frequency point estimates of pfmdr1 N86Y/D1246Y haplotypes. Error 
bars represent 95% credible intervals.  
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Supplemental Figure 3. Frequency point estimates of pfmdr1 N86Y/D1246Y haplotypes with 
pfcrt K76T. Error bars represent 95% credible interval.  
 
 
 
